Table 3.
Follow-up, time to outcome, and hazard ratios of progression and/or death in selected studies.
| Author | Year | Median Follow-Up (Months) | Median PFS (Months) | HR | CI | P | Median OS (Months) |
HR | CI | P |
|---|---|---|---|---|---|---|---|---|---|---|
| Kim J. | 2005 | 28 | NR | 1.35 | 1.09–1.68 | 0.0065 | High 9; Low 23 |
2.53 | 1.19–5.40 | 0.016 |
| Ottaiano A. | 2006 | 23 | NR | 3.01 | 0.88–5.21 | 0.0991 | NR | |||
| Yoshitake N. | 2008 | NR | 5.08 | 0.65–40.00 | 0.123 | |||||
| Speetjens F.M. | 2009 | NR | NR | 2 | 1.1–3.7 | 0.03 | NR | 1.8 | 1–3.6 | 0.07 |
| Speetjens F.M. | 2009 | NR | NR | 2.6 | 1–6.2 | 0.04 | NR | 3.7 | 1.35–11 | 0.02 |
| Ingold B. | 2009 | 32 | NR | 2.87 | 1.31–6.29 | 0.009 | ||||
| Wang SC. | 2010 | 61 | 5 years DFS rate: High 70%; Low 55% (Nuc CXCR4) |
1.23 | 0.7–2.18 | 0.458 | ||||
| Yopp A.C. | 2012 | 68 | Pos. 15 vs Neg. 73 | 2.2 | 1.2–4.2 | 0.012 | ||||
| Sakai N.* | 2012 | 38 | 3 years OS rate: High 67%; Low 78% |
Cyto: 0.43 | Cyto: 0.18–1.02 | Cyto: 0.056 | ||||
| Sakai N.* | 2012 | 38 | 3 years OS rate: Pos 93%; Neg 67% |
Nuc: 4.05 | Nuc: 1.19–13.8 | Nuc: 0.025 | ||||
| Du C.* | 2014 | 68.5 | 5 years DFS rate: High 76.8%; Low 84.3% |
0.81 | 0.36–1.8 | 0.618 | ||||
| Gao Y. | 2014 | NR | 1.3 | 1.38–1.85 | 0.001 | |||||
| Stanisavljevic L.* | 2015 | Min from 3–5 years | 5 years DFS rate: High 65%; Low 85% |
0.42 | 0.22–0.78 | 0.006 | ||||
| Stanisavljevic L.* | 2015 | Min from 3–5 years | High 82%; Low 89% |
0.89 | 0.31–2.61 | 0.838 | ||||
| D′Alterio C.* | 2016 | 28 | High 14 vs. Neg/Low 46 | 3.405 | 1.70–17.33 | 0.004 | High 28; Neg/Low 46 | 0.079 | 0.062–0.480 | 0.0008 |
| Wu W. | 2016 | Max 60 | NR | 5.38 | 2.42–9.13 | 0.002 | ||||
| Weixler B. | 2017 | NR | 5 years OS rate: High 48%; Low 48% |
0.99 | 0.99–1.0 | 0.322 | ||||
| Xu C.* | 2018 | NR | High 51; Low 54 | 0.188 | 0.03–0.75 | 0.020 | ||||
| Ottaiano A. | 2020 | 53 | High 19; Neg/Low 31 | 3.18 | 2.01–5.02 | 0.0312 |
* HR was transformed in forest plot (see Methods).CI: confidence interval; Cyto: cytoplasmic; DFS: disease-free survival; HR: hazard ratio; Neg: negative; NR: not reported; Nuc: nuclear; OS: overall survival.